Amazentis is an innovative life science company dedicated to employing breakthrough research and clinical science to bring advanced therapeutic nutrition products to life.
We employ rigorous science
to pioneer the discovery and clinical development of the next generation of naturally derived bioactives, starting with Mitopure™ (a proprietary highly pure Urolithin A). Our focus is the development of innovative products designed to meet the health needs of an aging population. Our current work builds on modulating Mitochondrial function.
We are improving muscle health
Our most advanced product targets the reversal of age-related muscle decline by improving the activity of mitochondria – the “powerhouse of the cell” – to optimize muscle function.
Society is aging. Worldwide,
it’s projected there will be more than 1 billion people over 65 years old by 2030.
A decline in skeletal muscle strength and overall function is a hallmark of aging. These changes can become debilitating and lead to a condition called sarcopenia, which is thought to affect 30% of elderly.
We are targeting a novel pathway
Our lead bioactive - a metabolite of pomegranates - has been demonstrated to trigger a highly effective biological mechanism of action that recycles and rejuvenates aging mitochondria via a process called mitophagy.
Our leadership
Includes world class scientists and medical professionals.
Our board features leading members of the Life Science and Pharmaceutical industries.
Patrick Aebischer, MD
Chairman and Co-Founder
Chris Rinsch, PhD
CEO and Co-Founder
Pierre Landolt
Co-Founder
Odile Rundquist, PhD
Thierry Lombard
Eric Lohrer
News
Press releases
Amazentis Announces the Launch of Timeline™ Cellular Nutrition at the World Economic Forum in Davos
Amazentis l Press Release l January 23rd 2020
First Human Clinical Trial Results on the Anti-Aging Compound, Urolithin A, Published by Amazentis and Researchers from the EPFL and SIB
Amazentis l Press Release l June 14th 2019
Nestlé Health Science invests in global strategic partnership with Amazentis to develop its new cellular nutrient Urolithin A
Amazentis l Press Release l April 2nd 2019
Amazentis SA Announces Completion of Series C Financing
Amazentis Also Announces Initiation of Two Pivotal, Phase 2 Clinical Studies in North America
Amazentis l Press Release l March 21st 2018
Amazentis SA Announces Successful Phase 1A/1B Study Results in Healthy Elderly Subjects with the Food Metabolite Urolithin A
Amazentis l Press Release l April 27th 2017
Milestone Study on Pomegranate Anti-Aging Mechanism Reported
by Amazentis SA and EPFL Researchers
Amazentis l Press Release l July 11th 2016
Pomegranate finally reveals its powerful anti-aging secret /
La grenade révèle une puissante molécule anti-vieillissement
EPFL l Press Release l July 11th 2016
Pomegranates reveal its powerful anti-aging secret
EPFL l Video l July 6th 2016
News
In the media
Pomegranate compound with anti-aging effects passes human trial
medicalxpress l Published online l June 17th 2019
The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans
Nature Metabolism l Published online l June 14th 2019
Nestle Deal Seeks to Tap Pomegranate's Anti-Aging Potential
Bloomberg l Published online l April 2nd 2019
Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents
Nature Medicine l Published online l July 11th 2016
Pomegranate by-product boosts muscles and may fight ageing
New Scientist l Published online l July 11th 2016
Gut bacteria unleash anti-aging power of pomegranates
Medical News Today l Published online l July 11th 2016
Discovery of pomegranate's anti-ageing molecule is a 'milestone'
Telegraph l Published online l July 11th 2016
Amazentis va commercialiser la «vitamine C» de l’anti-âge
Bilan l Published online l July 11th 2016
Pomegranate by-product boosts muscles and may fight ageing
Financial Times l Published online l July 12th 2016
Would you like to be informed when our products become available?
Terms of Use | Privacy Policy | All contents © Copyright Amazentis SA. All Rights Reserved
